All In Biotech

Drug Trial Radar · NCT05203224

Improving Early Reperfusion With Adjuvant Dornase Alfa in Large Vessel Ischemic Stroke (EXTEND-IA DNase)

Last checked: Nov 20, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

330

Actual

Start

Feb 18, 2022

Primary completion

Nov 24, 2025

Study completion Feb 25, 2026

Sponsor

Lead sponsor
University of MelbourneAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients presenting to the emergency department with acute ischemic stroke, who are are eligible for standard intravenous thrombolytic therapy within 4.5 hours of stroke onset will be assessed for major vessel occlusion to determine their eligibility for the trial. All participants will receive intravenous tenecteplase (or alteplase due to manufacturer shortage) and endovascular thrombectomy as standard care. The trial is a Bayesian Optimised Phase 2 dose-finding umbrella trial (single arm versus objective performance criterion of 20% substantial reperfusion prior to endovascular thrombectomy based on the EXTEND-IA TNK trials NCT02388061, NCT03340493). The aim is to determine the optimal dose of intravenous dornase alfa (recombinant human DNase 1) with sufficient promise to take forward in a seamless phase 2b/3 design.

Conditions

  • Ischemic Stroke

Interventions

  • Dornase AlfaDrug

    Intravenous Dornase alfa

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with substantial angiographic reperfusion or absence of retrievable intracranial thrombus at initial angiogram without symptomatic intracerebral hemorrhageTime frame: 24 hours post-treatment

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Princess Alexandra Hospital

    Brisbane, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Royal Melbourne Hospital

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.